Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243271 | 0.92 | CHRM2 (0.59) | CHRM2TAAR1MPOKMT2AMAPT | |
| SCHEMBL10725177 | 0.86 | TAAR1 (0.52) | CHRM2TAAR1SLC6A2HTR2AMPO | |
| SCHEMBL9201570 | 0.82 | CHRM2 (0.50) | CHRM2TAAR1MPOKMT2AMAPT | |
| SCHEMBL13159608 | 0.82 | CHRM2 (0.69) | CHRM2KMT2AHTTMEN1 | |
| Hydrochloric Acid SCHEMBL9207321 | 0.81 | CHRM2 (0.49) | CHRM2TAAR1MPOKMT2AMAPT | |
| SCHEMBL16268723 | 0.79 | CHRM2 (0.47) | CHRM2TAAR1SIGMAR1 | |
| SCHEMBL9490687 | 0.79 | CHRM2 (0.56) | CHRM2TAAR1DRD2SIGMAR1MAPT | |
| SCHEMBL22762073 | 0.78 | TAAR1 (0.63) | CHRM2TAAR1DRD2SIGMAR1SLC6A2 | |
| SCHEMBL11274247 | 0.78 | TAAR1 (0.48) | TAAR1DRD2SIGMAR1SLC6A2HTR2A | |
| SCHEMBL172293 | 0.78 | TAAR1 (0.63) | CHRM2TAAR1MPOKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189048-B1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020247860-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | AP2A1, P2RX5, AP3M1 | CHRM2 1154/4885TAAR1 1206/4885DRD2 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.